Modulation of sphingosine-1-phosphate receptor ameliorates harmaline-induced essential tremor in rat. 2017

Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
Intracellular Recording Lab, Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran; Department of Anatomical Sciences, Afzalipour Medical Faculty, Kerman University of Medical Sciences, Kerman, Iran.

Essential tremor (ET) is one of the most common movement disorders with unknown etiology. Despite lack of effective clinical treatments, some potential therapeutic factors and modulation of some neurotransmitters have been utilized to ameliorate motor symptoms in the animal models of tremor. In the current study, male Wistar rats (n=10 in each group) weighing 40-60g were divided into vehicle control groups (saline or DMSO), saline/DMSO+harmaline (30mg/kg, i.p.)+fingolimod (FTY720) (1mg/kg, i.p, 1h before harmaline injection) groups. Open field, rotarod, wire grip and foot print tests were used to evaluate motor function. The results demonstrated that administration of FTY720 can improve harmaline-induced tremor in rats. Moreover, FTY720 ameliorated gait disturbance. The results showed that FTY720 can recover step width, left and right step length; however, FTY720 failed to recover mobility duration. FTY720 also improved falling time and time spent in wire grip and rotarod, respectively. The current study provides the first evidence for the effectiveness of FTY720 on motor function in the harmaline model of ET. Furthermore, neuroprotective effects of FTY720 demonstrated in this study offer sphingosine-1-phosphate receptor (S1PR) modulators as a potential neuroprotective candidate against substance-induced tremor and a possible strategy for the treatment of patients with tremor.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006246 Harmaline A beta-carboline alkaloid isolated from seeds of PEGANUM. 3H-Pyrido(3,4-b)indole, 4,9-dihydro-7-methoxy-1-methyl-,Dihydroharmine,Harmidine
D000068876 Fingolimod Hydrochloride A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS. 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride,FTY 720,FTY-720,FTY720,Fingolimod,Gilenia,Gilenya
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
November 2016, British journal of pharmacology,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
January 2014, Basic and clinical neuroscience,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
June 2019, Neuroscience letters,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
April 2021, Neuroscience letters,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
May 2020, Cells,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
May 2021, Neuroscience letters,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
April 2022, International journal of molecular sciences,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
July 2012, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
April 2015, International journal of molecular medicine,
Narjes Dahmardeh, and Majid Asadi-Shekaari, and Shokouh Arjmand, and Tajpari Kalantaripour, and Mohsen Basiri, and Mohammad Shabani
April 2017, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
Copied contents to your clipboard!